" class="no-js "lang="en-US"> Christian Jung - Medtech Alert
Wednesday, October 01, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Christian Jung

Christian Jung

About Christian Jung

Christian joined the DDF as Partner in 2019 and led the investment in Transine. Christian joined the DDF from Wellington Partners and before that was a Senior Investment Manager with High-Tech Gründerfonds where he completed and led the investments in nine seed- and early-stage companies, including Amal Therapeutics (acquired by Boehringer Ingelheim in 2019), Rigontec (acquired by MSD in 2017) and Cunesoft (acquired by Phlexglobal in 2019).

Related Story

Diseases

 Transine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development | Pharmtech Focus

Transine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development

May 31 2022

Transine Therapeutics (‘Transine’), a biotechnology company developing a novel class of therapeutic RNAs based on […]